¼¼°èÀÇ Á¾¾ç À¯¹ß¼º °ñ¿¬È­Áõ ½ÃÀå
Tumor-Induced Osteomalacia
»óǰÄÚµå : 1795187
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 281 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,218,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,655,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Á¾¾ç À¯¹ß¼º °ñ¿¬È­Áõ ¼¼°è ½ÃÀåÀº 2030³â±îÁö 1¾ï 2,950¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 1¾ï 1,450¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â Á¾¾ç À¯¹ß¼º °ñ¿¬È­Áõ ¼¼°è ½ÃÀåÀº 2030³â¿¡´Â 1¾ï 2,950¸¸ ´Þ·¯¿¡ ´ÞÇϰí, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 2.1%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ÀǾàǰ ¹× º¸ÃæÁ¦ Ä¡·á´Â CAGR 2.5%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 8,790¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¿Ü°ú Ä¡·á ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 1.2%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 3,120¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 4.0%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ Á¾¾ç À¯¹ß¼º °ñ¿¬È­Áõ ½ÃÀåÀº 2024³â¿¡ 3,120¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 2,430¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 4.0%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 0.8%¿Í 1.8%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 1.2%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ Á¾¾ç À¯¹ß¼º °ñ¿¬È­Áõ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

Á¾¾ç À¯¹ß¼º °ñ¿¬È­ÁõÀÌ ³»ºÐºñÇÐ ¹× Á¾¾çÇп¡¼­ °íÀ¯ÇÑ µµÀüÀÌ µÇ´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

Á¾¾ç À¯¹ß¼º °ñ¿¬È­Áõ(TIO)Àº Á¾¾çÀÌ °úµµÇÑ FGF23À» ºÐºñÇÏ¿© ÀÎ»ê ¼Õ½Ç, ¾àÇÑ »À, ¸¸¼º ÅëÁõÀ» À¯¹ßÇÏ´Â µå¹® ÁúȯÀÔ´Ï´Ù. ¸·¿¬ÇÑ Áõ»ó°ú ÀÌ ÁúȯÀÇ ¿øÀÎÀÎ ÀÛ°í ´À¸®°Ô ÀÚ¶ó´Â Á¾¾çÀÇ À§Ä¡¸¦ ÆÄ¾ÇÇϱ⠾î·Á¿ö Áø´ÜÀÌ ´Ê¾îÁö´Â °æ¿ì°¡ ¸¹½À´Ï´Ù.

ÀÏ´Ü Á¾¾çÀÌ È®ÀεǸé, º¸Åë ¼ö¼ú·Î Á¾¾çÀ» Á¦°ÅÇϸé Áõ»óÀÌ »ç¶óÁý´Ï´Ù. ±×·¯³ª ¼ö¼úÀÌ ºÒ°¡´ÉÇÑ Á¾¾çÀ̳ª ¼û°ÜÁø Á¾¾çÀÇ °æ¿ì Àλ꿰°ú ºñŸ¹Î D º¸ÃæÁ¦¸¦ ÅëÇÑ Àå±âÀûÀÎ °ü¸®°¡ ÇÊ¿äÇÏÁö¸¸, ¿ÏÀüÇÑ È¸º¹À» À§Çؼ­´Â ÃæºÐÇÏÁö ¾ÊÀº °æ¿ì°¡ ¸¹½À´Ï´Ù.

Áø´Ü Çõ½Å°ú Ç¥Àû Ä¡·á°¡ TIO °ü¸®¸¦ ¾î¶»°Ô º¯È­½Ãų °ÍÀΰ¡?

¼Ò¸¶Å佺Ÿƾ ¼ö¿ëü¸¦ Ç¥ÀûÀ¸·Î ÇÏ´Â ÃßÀûÀÚ¸¦ ÀÌ¿ëÇÑ ¿µ»ó Áø´ÜÀÇ ¹ßÀüÀ¸·Î Á¾¾çÀÇ ±¹¼ÒÈ­°¡ °³¼±µÇ°í ÀÖ½À´Ï´Ù. FGF23À» ÃøÁ¤ÇÏ´Â Ç÷¾× °Ë»ç´Â Áúº´ÀÇ Áø´Ü°ú ÁøÇàÀ» ÃßÀûÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù.

FGF23À» ¾ïÁ¦ÇÏ´Â ´ÜŬ·ÐÇ×üÀÎ ºÎ·Î¼ö¸¿Àº ÀýÁ¦ ºÒ°¡´ÉÇÑ °æ¿ìÀÇ È¹±âÀûÀÎ Ä¡·á¹ýÀÔ´Ï´Ù. ÀÎ»ê ¼öÄ¡ ȸº¹, ÅëÁõ ¿ÏÈ­, ¿îµ¿ ´É·Â Çâ»ó, ¼ö¼úÀÌ ºÒ°¡´ÉÇÑ °æ¿ì Ç¥Àû Ä¡·á¸¦ Á¦°øÇÕ´Ï´Ù.

Á¾¾ç À¯¹ß °ñ¿¬È­Áõ ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµË´Ï´Ù...

½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀº Áø´Ü¹ý °³¼±, ÀÎÁöµµ Çâ»ó, ºÎ·Î¼ö¸¿°ú °°Àº »ý¹°ÇÐÀû Á¦Á¦ÀÇ ÃâÇöÀÔ´Ï´Ù. Èñ±ÍÁúȯ ¿¬±¸¿¡ ´ëÇÑ ÀÚ±Ý Áö¿ø°ú Á¤Ã¥Àû Àμ¾Æ¼ºêÀÇ Áõ°¡, º´¿ø, ¿¬±¸±â°ü, Á¦¾à»ç °£ÀÇ Çù·Â ü°è°¡ ÀÌ ¼Ò¿ÜµÈ ºÐ¾ß¿¡ ´ëÇÑ °ü½É°ú Çõ½ÅÀ» ºÒ·¯ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù.

ºÎ¹®

Ä¡·á(ÀǾàǰ¡¤º¸ÃæÁ¦ Ä¡·á, ¿Ü°ú Ä¡·á), ÃÖÁ¾»ç¿ë(º´¿ø ÃÖÁ¾»ç¿ë, ¿Ü·¡ ¿Ü°ú ¼¾ÅÍ ÃÖÁ¾»ç¿ë, Àü¹® Ŭ¸®´Ð ÃÖÁ¾»ç¿ë, ±âŸ ÃÖÁ¾»ç¿ë)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM ¹× ¾÷°èº° SLM Äõ¸®¸¦ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Tumor-Induced Osteomalacia Market to Reach US$129.5 Million by 2030

The global market for Tumor-Induced Osteomalacia estimated at US$114.5 Million in the year 2024, is expected to reach US$129.5 Million by 2030, growing at a CAGR of 2.1% over the analysis period 2024-2030. Drugs & Supplements Treatment, one of the segments analyzed in the report, is expected to record a 2.5% CAGR and reach US$87.9 Million by the end of the analysis period. Growth in the Surgery Treatment segment is estimated at 1.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$31.2 Million While China is Forecast to Grow at 4.0% CAGR

The Tumor-Induced Osteomalacia market in the U.S. is estimated at US$31.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$24.3 Million by the year 2030 trailing a CAGR of 4.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.8% and 1.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.2% CAGR.

Global Tumor-Induced Osteomalacia Market - Key Trends & Drivers Summarized

Why Is Tumor-Induced Osteomalacia a Unique Challenge in Endocrinology and Oncology?

Tumor-Induced Osteomalacia (TIO) is a rare disorder where tumors secrete excess FGF23, causing phosphate loss, weak bones, and chronic pain. Diagnosis is often delayed due to vague symptoms and the difficulty of locating small, slow-growing tumors responsible for the condition.

Once identified, surgical removal of the tumor usually resolves symptoms. However, inoperable or hidden tumors require long-term management with phosphate and vitamin D supplements, which are often insufficient for full recovery.

How Are Diagnostic Innovations and Targeted Therapies Changing TIO Management?

Imaging advances using somatostatin receptor-targeted tracers are improving tumor localization. Blood tests measuring FGF23 have become essential for diagnosing and tracking disease progression.

Burosumab, a monoclonal antibody that blocks FGF23, is a game-changing therapy for non-resectable cases. It restores phosphate levels, reduces pain, and improves mobility, offering targeted treatment where surgery is not an option.

The Growth in the Tumor-Induced Osteomalacia Market Is Driven by Several Factors…

Market growth is driven by improved diagnostics, awareness, and the emergence of biologics like burosumab. Rare disease research funding and policy incentives are increasing. Collaborative efforts among hospitals, research institutions, and pharmaceutical companies are bringing more attention and innovation to this neglected segment.

SCOPE OF STUDY:

The report analyzes the Tumor-Induced Osteomalacia market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment (Drugs & Supplements Treatment, Surgery Treatment); End-Use (Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â